The recently published article in SPIEGEL highlights a concerning issue: The avian flu H5N1 has claimed a human life in the USA. A stark reminder of how real the danger of future pandemics is. 𝗔𝘁 𝗠𝘂𝗰𝗼𝘀𝗮𝗧𝗲𝗰, 𝘄𝗲 𝗵𝗮𝘃𝗲 𝗮 𝗺𝗶𝘀𝘀𝗶𝗼𝗻: We are developing a therapeutic solution against H5N1 that could help curb such epidemics and … Read more
On 29-30 August 2024, the Virus Biology and Biophysics Network gathered at the Helmholtz Centre for Infection Research in Braunschweig. MucosaTec GmbH proudly participated in this event as a sponsor and actively attended the talks, contributing to the exchange of groundbreaking research aimed at advancing the understanding of viral infections. With its innovative antiviral platform, … Read more
We are thrilled to announce that we have been selected as a finalist to pitch at the BARDA VITAL Global Health Security Symposium on June 27 in Berlin. This event focuses on visionary advancements in vaccine and therapeutics innovation, and medical countermeasures aimed at enhancing pandemic preparedness and response for a safer future. Join us … Read more
Last week, Marius Hittinger represented MucosaTec at the Start-up Prize of Science & Startups Berliner Sparkasse. He presented our technology, business model, financing strategies and development opportunities to an expert panel. The Berliner Sparkasse Prize is awarded annually and is a significant milestone for the university-based startup scene in Berlin. The best teams formed over the past year from the … Read more
MucosaTec was invited to Venture SPRIND 2024 in Berlin on April 24th, 2024. The event will bring together over 300 business angels, VCs, and venture debt investors to meet 45 teams from the SPRIND portfolio. The presence of political guest Robert Habeck, German Federal Minister for Economic Affairs and Climate Action, adds even more significance … Read more
Bionity.com reports in the news about MucosaTec winning the Innovation Award 2024. MucosaTec’s technology comprises novel bifunctional peptides that provide a flexible and cost-effective method of combating viral infections. The peptides bind to both the pathogen and the mucus, our body’s natural barrier, and thus immobilize pathogens. This innovation could form the basis for the … Read more
A major daily newspaper in Berlin, Germany, the “Berliner Zeitung”, reports on its homepage about MucosaTec winning the Innovation Award 2024. The BioRegions prize is awarded for outstanding research results and inventions with high innovation potential. MucosaTec’s technology comprises novel bifunctional peptides that provide a flexible and cost-effective method of combating viral infections.
This first edition of the founders award will be awarded on June 26th, 2024 from 6:00 p.m. in the beautiful premises of the “Berliner Sparkasse am Wannsee” (Kronprinzessinnenweg 21). An event in this constellation marks a significant milestone for Berlin’s university start-up scene and shows the enormous potential that exists in Berlin. The best nine … Read more
The esteemed BioRegions Innovation Prize 2024 was proudly presented to the MucosaTec team. Our groundbreaking patent for bifunctional peptides showcases a revolutionary technology that offers a flexible and cost-effective approach to combating viral infections. These peptides bind to both pathogens and our mucus, effectively immobilizing pathogenes. The award ceremony for this prestigious recognition took place … Read more
© COPYRIGHT MUCOSATEC
